Your browser doesn't support javascript.
Risk factors for neuropsychiatric symptoms in patients with Parkinson's disease during COVID-19 pandemic in Japan.
Kitani-Morii, Fukiko; Kasai, Takashi; Horiguchi, Go; Teramukai, Satoshi; Ohmichi, Takuma; Shinomoto, Makiko; Fujino, Yuzo; Mizuno, Toshiki.
  • Kitani-Morii F; Department of Molecular Pathobiology of Brain Diseases, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Kasai T; Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Horiguchi G; Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Teramukai S; Division of Data Science, The Clinical and Translational Research Center, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Ohmichi T; Division of Data Science, The Clinical and Translational Research Center, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Shinomoto M; Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Fujino Y; Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Mizuno T; Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
PLoS One ; 16(1): e0245864, 2021.
Article in English | MEDLINE | ID: covidwho-1042710
ABSTRACT
The worsening of neuropsychiatric symptoms such as depression, anxiety, and insomnia in patients with Parkinson's disease (PD) has been a concern during the COVID-19 pandemic, because most people worked in self-isolation for fear of infection. We aimed to clarify the impact of social restrictions imposed due to the COVID-19 pandemic on neuropsychiatric symptoms in PD patients and to identify risk factors associated with these symptoms. A cross-sectional, hospital-based survey was conducted from April 22, 2020 to May 15, 2020. PD patients and their family members were asked to complete paper-based questionnaires about neuropsychiatric symptoms by mail. PD patients were evaluated for motor symptoms using MDS-UPDRS part 2 by telephone interview. A total of 71 responders (39 PD patients and 32 controls) completed the study. Although there was no difference in the age distribution, the rate of females was significantly lower in PD patients (35%) than controls (84%) (P < 0.001). Participants with clinical depression (PHQ-9 score ≥ 10) were more common in PD patients (39%) than controls (6%) (P = 0.002). Multivariate logistic regression analysis revealed that an MDS-UPDRS part 2 score was correlated with the presence of clinical depression (PHQ-9 score ≥ 10) and clinical anxiety (GAD-7 score ≥ 7) (clinical depression OR, 1.31; 95% CI, 1.04-1.66; P = 0.025; clinical anxiety OR, 1.36; 95% CI, 1.07-1.72; P = 0.013). In the presence of social restrictions, more attention needs to be paid to the neuropsychiatric complications of PD patients, especially those with more severe motor symptoms.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Anxiety Disorders / Parkinson Disease / Depressive Disorder / COVID-19 / Sleep Initiation and Maintenance Disorders Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Aged / Female / Humans / Male Country/Region as subject: Asia Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0245864

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Anxiety Disorders / Parkinson Disease / Depressive Disorder / COVID-19 / Sleep Initiation and Maintenance Disorders Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Aged / Female / Humans / Male Country/Region as subject: Asia Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0245864